Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first site, Dedicated to Women OB/GYN in Dover, Del., has begun enrollment.
Pearsanta President Chris Mitton stated that this milestone supports the validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. Endometriosis affects approximately 1 in 10 women of reproductive age and often goes undiagnosed for years due to the invasive nature of the current gold standard, laparoscopy. A blood-based test could significantly reduce diagnostic delays and improve patient outcomes.
The study's design aims to demonstrate the accuracy and reliability of MET in detecting endometriosis, potentially offering a less invasive and more accessible option for patients. If successful, the test could transform the diagnostic landscape for endometriosis, allowing for earlier intervention and better management of the condition.
For more details, the full press release is available at https://ibn.fm/WiIhM.
Aditxt operates as a social innovation platform accelerating promising health innovations. Its ecosystem includes research institutions, industry partners, and shareholders working collaboratively to advance innovations in autoimmunity, cancer detection, infectious diseases, and women's health. The company's unique model focuses on democratizing innovation and empowering collective progress.
This clinical study represents a significant step toward addressing a major unmet need in women's health. If MET receives regulatory approval, it could become a widely used tool for early detection, potentially reducing the diagnostic odyssey many patients face. The implications of this announcement extend beyond the company, highlighting the growing trend toward non-invasive diagnostics and precision medicine.
Investors and stakeholders can find the latest news and updates regarding ADTX in the company's newsroom at https://ibn.fm/ADTX.
